Persistent URL of this record https://hdl.handle.net/1887/96587
In Collections
This item can be found in the following collections:
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
- All authors
- Bent, M.J. van den; Klein, M.; Smits, M.; Reijneveld, J.C.; French, P.J.; Clement, P.; Vos, F.Y.F. de; Wick, A.; Mulholland, P.J.; Taphoorn, M.J.B.; Lewis, J.; Weller, M.; Chinot, O.L.; Kros, J.M.; Heer, I. de; Verschuere, T.; Coens, C.; Golfinopoulos, V.; Gorlia, T.; Idbaih, A.
- Date
- 2018-09-30
- Journal
- The Lancet Oncology
- Volume
- 19
- Issue
- 9
- Pages
- 1170 - 1179